- Home
- HRMY vs ICFI Comparison
HRMY vs ICFI Comparison
Compare HRMY & ICFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- ICFI
- Stock Information
- Founded
- HRMY 2017
- ICFI 1969
- Country
- HRMY United States
- ICFI United States
- Employees
- HRMY N/A
- ICFI N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- ICFI Professional Services
- Sector
- HRMY Health Care
- ICFI Consumer Discretionary
- Exchange
- HRMY Nasdaq
- ICFI Nasdaq
- Market Cap
- HRMY 2.0B
- ICFI 1.6B
- IPO Year
- HRMY 2020
- ICFI 2006
- Fundamental
- Price
- HRMY $35.31
- ICFI $84.12
- Analyst Decision
- HRMY Strong Buy
- ICFI Buy
- Analyst Count
- HRMY 9
- ICFI 4
- Target Price
- HRMY $54.22
- ICFI $115.50
- AVG Volume (30 Days)
- HRMY 738.5K
- ICFI 182.5K
- Earning Date
- HRMY 05-06-2025
- ICFI 05-01-2025
- Dividend Yield
- HRMY N/A
- ICFI 0.66%
- EPS Growth
- HRMY 13.13
- ICFI 18.33
- EPS
- HRMY 2.62
- ICFI 5.82
- Revenue
- HRMY $744,852,000.00
- ICFI $2,012,969,000.00
- Revenue This Year
- HRMY $20.35
- ICFI N/A
- Revenue Next Year
- HRMY $17.42
- ICFI $1.49
- P/E Ratio
- HRMY $13.46
- ICFI $14.09
- Revenue Growth
- HRMY 20.62
- ICFI 1.95
- 52 Week Low
- HRMY $26.47
- ICFI $75.91
- 52 Week High
- HRMY $41.61
- ICFI $179.67
- Technical
- Relative Strength Index (RSI)
- HRMY 61.62
- ICFI 46.40
- Support Level
- HRMY $33.47
- ICFI $84.19
- Resistance Level
- HRMY $35.35
- ICFI $86.38
- Average True Range (ATR)
- HRMY 1.09
- ICFI 2.39
- MACD
- HRMY -0.01
- ICFI -0.40
- Stochastic Oscillator
- HRMY 70.34
- ICFI 35.22
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About ICFI ICF International Inc.
ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian & Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in a single segment, which is providing professional services.